ENPICOM Announces Expansion of IGX Platform

ENPICOM, an innovative bioinformatics software engineering company, announced the upcoming expansion of the IGX Platform’s capabilities towards advanced liability prediction. At the Antibody Engineering and Therapeutics virtual conference, the company revealed its plans to integrate the Structural Antibody Prediction Platform (SAbPred) developed by researchers at the University of Oxford.

SAbPred is a widely recognized and validated tool developed by experts in molecular biology. While our team harbors a lot of knowledge in bioinformatics and software engineering, we believe this powerful combination brings the best of the two worlds. We are elevating our current platform capabilities and deliver an exceptional experience to antibody and vaccine developers looking for a more rapid, efficient, and reliable antibody discovery solution.” said Jos Lunenberg, co-founder and Chief Executive Officer at ENPICOM.

“We’re very excited to see Oxford Protein Informatics Group’s SabPred tools incorporated into ENPICOM’s IGX Platform. This collaboration will open the door for new users to apply our software to the structural analysis of antibodies.” said Fergus Boyles, Research Software Engineer at University of Oxford.

Enabling structural liability analysis at scale
Oxford researchers have developed SAbPred to perform various predictions of antibody properties that can support the discovery process and antibody design. The software helps study antibody properties and generate valuable information for developability potential of antibody candidates. SAbPred is currently used by leading biopharmaceutical companies to improve the design of antibody-based therapeutics.

By integrating SAbPred tools into the IGX Platform, ENPICOM allows scientists to apply the sophisticated algorithms to analyze high-throughput sequencing data inside the scalable and intuitive environment. This integration unlocks new antibody discovery workflows like performing structural analysis of proteins of interest and annotating important liability characteristics to select antibody candidates with good developability properties.

“The integration of SAbBox technology with ENPICOM’s IGX platform is great case study for impact from research at the Oxford University. We look forward to this launch as it will provide new ways of accessing the SabPred tools on a cloud-based platform.” said Sandeep Singh, Senior Licensing and Ventures Manager at Oxford University Innovation.

To learn more about the announcement at the Antibody Engineering and Therapeutics virtual conference, view the on-demand recording of the speaking session here.

SourceENPICOM
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Thermo Scientific™ Dionex™ Inuvion™ Ion Chromatography (IC) system, helping to make ion analysis simpler and more intuitive for labs of all sizes. The new analytical instrument is designed to be easily reconfigurable, providing those who require determination of ionic and small polar compounds with a one stop shop for consistent, reliable ion analysis.
This new collaboration is another example of Blacksmith's creative deal-making with top tier partners that bring expertise to the table which helps de-risk and accelerate scientific discoveries for the development of valuable products.
Heparin Sodium 2,000 units in 0.9% Sodium Chloride Injection 1,000 mL (2 units/mL), is indicated as an anticoagulant to maintain catheter patency.
Through this agreement, RaySearch acquires full ownership of all rights to the product DrugLog for its application in the field of oncology, including the measuring device, calibration parameters, source code, as well as intellectual property rights.
Anna Kazanchyan, MD, Founder and CEO of Saghmos Therapeutics. "We are very pleased to announce the Notice of Allowance for our second patent, which will enhance the long-term value of ST-62516. Saghmos continues to build its intellectual property estate."

By using this website you agree to accept Medical Device News Magazine Privacy Policy